国产精品国产一级毛片_亚洲AⅤ永久无码精品毛片69_亚洲最新a级片在线观看_91丨国产丨白丝_亚洲一级片免费在线观看_三级片免费看国产_欧美精品一级视频_北条麻妃久久99精品_无码中文字幕伊人_精品区免费视频亚洲

About US

關于我們

Company Overview

      Hainan Poly Pharm Co. Ltd. is a leading pharmaceutical company in China,dedicated to providing therapeutic-value products and services to patients and customers around the world, which mainly involves in the activities of R&D, manufacturing and marketing.
       Founded in 1992, Poly has built up an excellent product portfolio with producing both Active Pharmaceutical Ingredient (API) and finished products, and gained great reputation for its high-quality products. Poly initiated its international registration program in 2005. Since 2012, Poly has received inspections from authorities including US FDA, EU EMA, NMPA and WHO with positive outcoming, which has provided sound evidence of Poly's GMP compliance in practice and its efforts in quality control.

      With the approval of products for marketing by EU EMA and US FDA, and distribution of its products to EU markets, Poly has already marched into the global market. In 2017, Poly Pharm successfully completed Initial Public Offering (IPO) and listed in Shenzhen Stock Exchange ( 300630.SZ)

  • 30

     

    Exporting countries and regions

  • 157

     

    Production permits for preparations to overseas markets

  • 97

     

    Innovation and invention patent

 

POLY Pharm Group

  • Hainan Poly Pharm (Manufacture)

  • Zhejiang Poly Pharm (Manufacture)

  • Anhui Poly Pharm (Manufacture)

  • Zhejiang Roly Pharm (Marketing&Sales)

Our Core Values

  • Faith

    Good Medicine. Healthy People

  • Mission

    Provide high-quality to the customers and patients all around the world

  • Core Values

    Honesty, Efficiency, Innovation, Professionalism

  • Vision

    To become a leading supplier of the products for specific indications

Our Strategy

  • Globalization

    Global generic drugs, global 505 (b) (2) drugs, global innovative drugs, global traditional Chinese medicine

  • Vertical industrial chain

    Quality assurance, patent challenge, innovative drugs and CDMO, first generics, technical breakthrough, cost advantage

  • BD positioning

    Global manufacturing/global sales, global interests, wholly-owned registration, global industrialization regulatory capacity, global industrialization capacity

  • Big data management

    Discovery of knowledge, establishment of models/patterns/templates, data analysis (experience), data model (rational) decision-making